Understanding the interactions between human immune cells and tumors is paramount when devising treatment strategies that prevent tumor evasion of immune cells and improve cytotoxic responses.
In this workshop you will find:
James Keck, Senior Director for the Clinical Lab & In Vivo Pharmacology Services, The Jackson Laboratory
The deadliest cancers are often characterized by significant intratumoral heterogeneity, which is often increased in metastases or recurrent tumors. Comprehending the mechanisms of heterogeneity and the patterns of divergence in tumor subtypes will be a significant factor in designing the next generation of anti-tumor therapeutics, including immunotherapies and small molecule inhibitors
In this workshop you will learn:
Joshua Breunig, Assistant Professor, Cedars-Sinai Medical Center
Joshua Breunig, PhD, is an Assistant Professor at Cedars-Sinai Medical Center with a joint appointment in the Department of Medicine at the David Geffen School of Medicine at UCLA. Dr. Breunig received his Ph.D. from Yale University. Currently, he investigates the transcriptional regulation of neural precursor cells (NPCs) in the brain, specifically exploring the pathways governing the transformation of NPCs into brain tumor progenitors. Using a next generation brain tumor models, his lab introduces patient-specific mutations to create “personalized” tumors in immunocompetent animal models. Dr. Breunig is supported by funding from the American Cancer Society, and NIH/NCI.
Simon Knott, Assistant Professor & Associate Director, Center for Bioinformatics and Functional Genomics, Cedars Sinai Medical Center
Simon Knott, PhD, is an assistant professor and associate director of the Center for Bioinformatics and Functional Genomics at Cedars Sinai Medical Center. Dr. Knott combines computational biology and functional genomics to elucidate the molecular mechanisms that drive cancer progression. Work in his laboratory is focused on three main areas: heterogeneity in cancer cell populations and how it impacts disease outcome, hetero-cellular interactions that allow cancer cells to manipulate the tumor microenvironment to evade therapy, and the development of novel computational and molecular tools to study disease progression